“We see the pathways of PD-1 resistance being explored across oncology. Kidney cancer is not especially leading the way on that,” says Mayer Fishman, MD, PhD.
In this video, Mayer Fishman, MD, PhD, discusses some current unmet needs in the kidney cancer space. Fishman is a medical oncologist at Tampa General Hospital Cancer Institute in Tampa Bay, Florida.
Video Transcript:
Brain disease patients, that's still an unmet need. It's very ad hoc. So, when there's some brain disease, we're going to treat them. Then you just go to the trials, where every single trial excluded patients with brain disease. We'll do what we can. There's not a lot of empiric things on that. We see the pathways of PD-1 resistance being explored across oncology. Kidney cancer is not especially leading the way on that. Who should have LAG3? How does the VEGF blockade mediate a more permissive immune environment? What can you do to drill down on what's going on in the tumor before you make a decision to give immune therapy? We tried to do it early on with the PD-1 medicines. The effort is still ongoing. It's still an unmet need to have someone walk in and say, “Oh, we checked this. In clear cell kidney cancer, PD-L1, that's not going to do it. Tumor infiltration, not especially.” So, those are some of the things I’d like to see.
This transcription has been edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.